Connect with us

International Circuit

Mylan Prevails in Copaxone Litigation Against Teva in US Appellate Court

Mylan N.V. announced that the United States Court of Appeals for the Federal Circuit has affirmed the District of Delaware’s decision that Teva’s Copaxone 40 mg/mL dosing patents are invalid as obvious. The Federal Circuit also affirmed today the final written decisions issued by the Patent Trial and Appeal Board in three inter partes reviews filed by Mylan related to the same patents. These were the last remaining patent infringement cases Mylan was defending in the US relating to Glatiramer Acetate Injection 40mg/mL. Today’s decisions are important milestones as we continue to focus our efforts on meeting the needs of multiple sclerosis patients in the US with Mylan’s more affordable treatment option.

The invalidated patents are US Patent Numbers 8,232,250; 8,399,413; 8,969,302; and 9,155,776, which are owned by Yeda Research & Development Co., Ltd. and licensed to Teva Pharmaceuticals Industries, Ltd. Copaxone is the most prescribed MS treatment for relapsing forms of MS in the US with brand sales for the 20 mg/mL dose of approximately USD 527 million and for the 40 mg/mL dose of approximately USD 2.86 billion for the 12 months ending Aug. 31, 2018, according to IQVIA. Approximately 400,000 individuals in the US have MS and relapsing MS accounts for 85 percent of initial MS diagnoses. – Medical Buyer Bureau

Copyright © 2024 Medical Buyer

error: Content is protected !!